The Activation of Brown and Beige Fat and Role in Insulin Sensitivity
Phase of Trial: Phase 0
Latest Information Update: 03 Jun 2017
At a glance
- Drugs Mirabegron (Primary) ; Pioglitazone (Primary)
- Indications Metabolic syndrome; Obesity
- Focus Biomarker; Pharmacodynamics
- 24 May 2017 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
- 24 May 2017 Status changed from not yet recruiting to recruiting.
- 05 Oct 2016 New trial record